Advances in Polyconjugate Vaccine Development: Leveraging SEC-MALS for Enhanced Quality Control and Efficacy

The upcoming webinar will delve into the latest advancements in pneumococcal polysaccharide vaccines and pneumococcal conjugate vaccines (PCVs), focusing on their development, production, and quality control. Key topics include the introduction of a new USP general chapter for the SEC-MALS method, the challenges of serotype replacement, and the evolution of PCVs to include more serotypes.

The session will explore the critical role of SEC-MALS in ensuring vaccine consistency and stability, highlighting its advantages over traditional analytical techniques, as well as the benefits of FFF-MALS for ultra-high molecular weight PCV analysis.

Key Learning Objectives:

• Understanding Pneumococcal Vaccines: Gain insights into the differences between pneumococcal polysaccharide vaccines and PCVs, their historical development, and their impact on public health.
• Challenges in Vaccine Development: Learn about serotype replacement and the on-going efforts to develop vaccines that cover a broader range of serotypes.
• Analytical Techniques: Explore the advantages of using SEC-MALS for multi-attribute quantification of vaccines, including its role in process development and quality control.
• Future Directions: Discover the latest advancements in PCV development, including the push towards 30+ valent vaccines and the role of emerging technologies in vaccine production.

Who Should Attend:

• Vaccine Researchers: Researchers involved in vaccine development will benefit from understanding the latest advancements in pneumococcal vaccines and the analytical techniques used to ensure their efficacy and safety.
• Quality Control Specialists: Professionals responsible for the quality control of vaccines will gain valuable insights into the use of SEC-MALS for monitoring vaccine consistency and stability.
• Pharmaceutical Manufacturers: Individuals working in the production and development of vaccines will find the discussion on new analytical methods and the challenges of serotype replacement crucial for improving vaccine formulations.

Presenter: Katayoun Morakabi, Ph.D. (Application Scientist)

Katayoun Morakabi (Kat) is an application scientist on the Analytical Sciences team at Wyatt Technology, a portfolio of Waters corporation. Kat assists customers in identifying the best light scattering solutions for their analytical needs by performing feasibility studies and leveraging her expertise in multi-angle light scattering. She earned her Ph.D. in Biochemistry from the University of Texas at Dallas, where her doctoral research focused on characterizing the structure, dynamics, and functional outcomes of proteins. If you attend Light Scattering University at Wyatt's headquarters in Santa Barbara, you might meet Kat in person as one of your instructors.